Tag: Novartis
Sandoz to acquire GSK’s cephalosporin antibiotics business in $500m worth deal
Sandoz, a division of Swiss pharma giant Novartis, has agreed to acquire GSK’s cephalosporin antibiotics business in a deal worth up to $500 million. The ... Read More
Novartis to acquire neuroscience company Cadent Therapeutics in $770m worth deal
Novartis acquisition of Cadent Therapeutics : Swiss pharma giant Novartis has agreed to acquire a US neuroscience company Cadent Therapeutics, in a deal worth up ... Read More
Novartis acquires optogenetics gene therapy company Vedere Bio
Novartis acquisition of Vedere Bio : US-based stealth-stage company Vedere Bio has been acquired by Swiss pharma giant Novartis in a deal worth up to ... Read More
Novartis reports positive results for Aimovig in phase 2 episodic migraine trial
Novartis said that a five-year phase 2 clinical trial of migraine prevention drug Aimovig (erenumab-aooe) has delivered strong long-term safety and efficacy results in patients ... Read More
BioNTech to acquire Novartis’ Marburg manufacturing plant to expand production of COVID-19 vaccine candidates
Biopharmaceutical New Technologies (BioNTech) has agreed to acquire a GMP certified manufacturing facility in Marburg, Germany from Novartis to expand the production capacity of its ... Read More
Novartis bags Kesimpta FDA approval for relapsing forms of MS
Kesimpta FDA approval for RMS: Novartis has bagged approval from the US Food and Drug Administration (FDA) for its blood cancer drug Kesimpta (ofatumumab, formerly OMB157) ... Read More
TScan, Novartis to develop T cell receptor therapies for solid tumors
TScan Therapeutics has partnered with Swiss pharma giant Novartis to discover and develop novel TCR-engineered T cell receptor therapies for the treatment of solid tumors ... Read More
Incyte to launch ruxolitinib coronavirus clinical trial in US
Ruxolitinib coronavirus clinical trial : Incyte revealed that it is working with the US Food and Drug Administration (FDA) to launch the phase 3 RUXCOVID ... Read More
Novartis to acquire The Medicines Company for $9.7bn with eye on inclisiran
Novartis acquisition of The Medicines Company : Swiss drugmaker Novartis signed a deal worth $9.7 billion to acquire US biopharma company The Medicines Company, as ... Read More
Novartis bags Adakveo FDA approval to reduce VOCs in sickle cell disease
Adakveo FDA approval : Swiss drugmaker Novartis has bagged approval for Adakveo (crizanlizumab-tmca) from the US Food and Drug Administration (FDA) for its use in ... Read More